FierceBiotech

Hope springs toward Parkinson's phase 3 despite divergent stem cell therapy data

Hope Biosciences has linked its stem cell therapy candidate to improved motor function in Parkinson’s disease patients in a phase 2 trial. The single-site study randomized 60 people with early to ...
Business Wire

First FDA-Approved Phase II Stem Cell Treatment Study Shows Significant Improvements in Progressive MS Patients

NEW YORK--(BUSINESS WIRE)--The Tisch MS Research Center of New York, the world’s largest MS research center, has announced publication of the results of its FDA-approved Phase II stem cell treatment ...
Business Wire

FDA-Approved Phase II Stem Cell Treatment Trial Shows Significant and Diverse Improvements for Multiple Sclerosis (MS) Patients

NEW YORK--(BUSINESS WIRE)--The Tisch MS Research Center of New York, the world’s largest independent research center focused on MS, today announced the Phase II results of its FDA-approved stem cell ...